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stenosis, 1 duodenal stenosis). Biliary lithiasis was observed in 5 patients (9.8%),
whereas 1 developed a post-transplantation, drug-induced pancreatitis. No bilio-
pancreatic malformations were detected in 33 patients (64.6%); a family history of
chronic pancreatitis was observed in 43.3% of them. Furthermore, genetic analysis
showed mutations in CFTR, SPINK1 and PRSS1 genes in 31%, 7.7% and 3.6%
of patients, respectively. The sweat test identiﬁed border-line values in 23.3% of
patients, allowing a diagnosis of atypical CF.
Conclusions: In 33 pediatric patients affected by RIP we observed high percentages
of familial/hereditary pancreatitis (43.3%) and atypical CF (23.3%). Genetic testing
conﬁrmed the high frequency of CFTR mutations and has been reported to be useful
in the detection of atypical forms of CF. An early diagnosis of atypical CF allows
a better quality of life and prognosis.
P48 CAN CYCLOSPORINE TREATMENT AFFECT CYSTIC FIBROSIS
PULMONARY DISEASE? A CASE REPORT
F. De Robertis, R. Tesse, A. Manca, M.R. Abrusci, B. Lauria, A. Capolongo,
V. Quarta, E. Dermyshi, L. Armenio. Department of Biomedicina dell’Eta`
Evolutiva, Pediatric Unit “S. Maggiore”, University of Bari, Italy
Case: A 28-year-old female cystic ﬁbrosis (CF) patient (R334W/852del22) came to
our CF referral Center in 1994. She presented with symptoms of prolonged acute
respiratory infections and recurrent episodes of pneumonia, and was treated with
ciproﬂoxacin and aminoglycosides. Sputum swabs samples were cultured and airway
colonization with Pseudomonas aeruginosa and Staphylococcua aureus was diag-
nosed. Pulmonary function tests documented a decrease in the mid-maximal ﬂow
rate, reﬂecting small airways obstruction and the mean forced expiratory volume in
1 sec value was 46% of predicted. Restrictive changes, characterized by declining
total lung capacity and vital capacity were also observed. Computed tomography
(CT) images of the chest showed that airway and parenchymal changes were present
throughout both lungs. Multiple areas of extensive bronchiectasis, atelectasis, mucus
plugging and defects of pulmonary vessels perfusion were seen in the left upper
lobe and in the right lower lobe. The patient required several hospital admissions for
pulmonary exacerbations and was regularly examinated at 2-month intervals. Her
CF was complicated by renal insufﬁciency (serum creatinine levels 4.4mg/dl) which
required long-term dialysis therapy. In March 2004 she underwent live-related donor
renal transplant and started an immunosuppressive therapy with cyclosporine. CT
images taken two years after transplantation documented a signiﬁcant size reduction
of bronchiectasis in the upper left lobe and a complete regression of atelectasis and
bronchiectasis in the lower right lobe. There were also signs of pulmonary perfusion
improvement in both lungs. The patient had lower mean serum creatinine values and
regained the weight lost during dialysis. Her pulmonary function improved from
46% predicted to 65% predicted. Since transplantation, she did not require any
hospitalization for pulmonary exacerbations and the interval between routine visits
was lengthened. This case highlights the fact that renal transplantation associated
with cyclosporine treatment may have beneﬁcial effect in terms of improvement of
lung damage progression in CF patient with renal failure. We also suggest that a
multicentric study may be proposed to treat with cyclosporine patients affected by
CF pulmonary disease.
P49 TELEMONITORING FEV1 AND PEF IN CYSTIC FIBROSIS
PATIENTS VERSUS FPR AMBULATORY
A. Manca, V. Bosco, M. Malvasi, M. Lorusso, L. Armenio. Centro Specializzato
di Riferimento Pugliese per la Fibrosi Cistica, U.O. “S. Maggiore” Universita` di
Bari, Bari, Italy
Introduction: The aim of this research has been to study the efﬁcacy of the
telemonitoring-assistance-therapy in Cystic Fibrosis patients, comparing it to the
standard medical care and therapy. We compared the homemade spirometry data
obtained by a monitoring system given to the CF patient and sent to a Data Centre,
using a telephone connection, with those made in our medical ambulatory, during
a clinical control.
Methods: For this demonstration we studied the values of FEV1 and PEF of 18 CF
patients. The ﬁrst spirometry, with following transmission, has been made during the
medical control in our ambulatory at the time of enrolment. All the used instruments
have been set according to the ATS standardisation. The data have been collected
using the Filemaker-Pro-7 database and elaborated with the software EPI-Info 6.00.
The t-student test has been used to assess the data with a p-value <0.05.
Results: From the ﬁrst data it seems that, for many patients, the examined
spirometry values are higher in the ambulatory made tests than in the homemade
ones, obtained without any medical control. The comparison among the average of
FEV1 does not show any statistically difference between the two groups (t = 0.9711,
pvalue = 0.3412). Those patients that precisely followed with care the protocol of the
study, at the end obtained similar spirometry as at home as at the FPR ambulatory.
A further conﬁrmation of this consideration comes from the comparison of PEF
values that is statistically signiﬁcant (t = 2.3415 p = 0.0278). This means that the
collaboration of the patient is different at home from the one offered in the
ambulatory.
Conclusions: In conclusion we can state that the medical control is useful to
perform the spirometry but with the acquisition, along the time, of the homemade
telemonitoring know-how, the patient becomes less dependent from the medical
presence and instructions.
P50 ATYPCAL CYSTIC FIBROSIS (ACF): AN EXPERIENCE OF A
CYSTIC FIBROSIS CENTER
V. Raia1, M. Siano1, R. Tomaiuolo2, F. De Gregorio1, A. Sepe1, P. Ferri1,
A. Elce2, G. Castaldo2. 1Dep. of Pediatrics, 2Dep. of Biochemistry and Medical
Biotechnology, Univ. of Naples Federico II-CEINGE, Italy
Introduction: During last decade an increased number of patients (pts) have been
diagnosed as ACF. According to the consensus opinion (Thorax 2006;61:627–635)
searching for ACF should start with sweat test (ST) in presence of suggestive
symptoms. If the ST is normal or border-line, a panel of at least 31 mutations
may help to diagnose ACF. A complete genetic analysis (GA) is indicated when
only one mutation is detected. Abnormal bioelectrical properties of nasal/intestinal
epithelium have to be performed in controversial cases.
Aim: To describe clinical and laboratory ﬁndings compatible with ACF in a cohort
of paediatric population followed at a CF Center.
Patients and Methods: CF Database data of 180 pts aged 1−18 years (y) identiﬁed
by symptoms after 1990 at Care Center were retrospectively reviewed. Inclusion
criteria for ACF were: sweat chloride level (SCL) < 60 mEq/l, clinical manifesta-
tions suggestive of CF at ﬁrst visit, two mutations or one mutation/polyT5/12TG
variant on both alleles by GA. 6 pts were ruled out despite suggestive symptoms
and ST <60mEq/l, because of only one detected mutation and so classiﬁed as
“CFTRpathies-correlated”. GA was based on a two level approach, as a ﬁrst analysis
of 31 mutations by ASO dot-blot followed by the scanning of the whole gene by
direct sequencing.
Results: Based on clinical ﬁndings, ST and GA 9 pts (4M, mean age at diagnosis
6.7 y, 18m-15y) were enrolled. All pts had pancreatic sufﬁciency (PS); mean value
of ﬁrst FEV1 (5/9) was 100, 3% with no PA colonization. 2/9 had pancreatitis
(PT) as ﬁrst manifestation. Mean value of SCL was 38.9 (24−50). 4/9 had severe
mutation/polymorphism (PolyT5/12TG).
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M 13 RRI,P 39 N1303K/D1152H HI 77 + B/P S,P
F 18m FTT,RRI 42.5 DF508/5T NP + B/P N
M 22m FTT,F 38 DF508/5T SA + B/P S
F 2.8 FTT,RRI 31 DF508/5T-9T NP + B/P NMH
F 15 RRI 46 W1282X/D1152H SA 97.6 + B/P NMH,S
M 11 PT 50 DF508/D1152H NP 97 + N N
F 4 RRI 34 D1152H/D1152H HI + B N
M 6 PT 24 E193/2997F HI 106 + B/P N
F 5.4 F,RRI 46 G542X/5T-9T SA 124 + B/P NMH
Legend: RRI recurrent respiratory infections; FTT failure to thrive; P polyps; S
sinusitis; F familiarity; HI Haemophilus Inﬂuentiae; SA Staphylococcus Aureus; PA
Pseudomonas Aeruginosa; B/P bronchitis/peribronchitis; NMH nasal mucosal hyper-
trophy; NP non pathogens; N negative.
Conclusions: Based on frequency of ACF diagnosis in adults, ACF should be
assessed also in children with suggestive symptoms of CF by SCL and GA.
P51 ANALYSIS OF FACTORS PROMOTING BONE DISEASE IN CYSTIC
FIBROSIS
A. Manca, F. De Robertis, B. Formato, B. Lauria, V. Quarta, E. Dermyshi, R. Tesse,
L. Armenio. Centro Specializzato di Riferimento Pugliese per la Fibrosi Cistica,
U.O. “S. Maggiore” Universita` di Bari, Bari, Italy
Introduction: Many Authors observed that cystic ﬁbrosis (CF) patients often are
at risk of fractures. Our aim was to establish factors involved in bone disease in
CF.
Methods: We enrolled 21 patients affected by CF (15 F and 6 M, age range 11−42
years). They have been distinguished for age, sex, respiratory function, pancreatic
function, serum calcium levels, 25OH vitD, PCR, T score and Z score, and DXA
scores. BMD Evaluation: Normal (T score between + 1 and −1), Osteopenia (T score
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between −1 and −2.5), Osteoporosis (T score <−2.5, with presence of fractures).
We used the Wilcoxon/Kruskal Wallis statistical test for analysis.
Results: First, we divided our patients in those with Osteopenia (n = 15) and those
affected by Osteoporosis (n = 6). Mean FEV1 values were signiﬁcantly higher in
patients affected by Osteopenia than in those affected by Osteoporosis (p = 0.05).
We found a positive correlation between BMI and Z score (r = 0.55 p = 0.0097),
suggesting that a good nutritional status affects the value of Z score. We then divided
patients based on pancreatic status. There was a positive correlation between FEV1
and Z score for pancreatic insufﬁciency, while subjects with pancreatic sufﬁciency
and mild clinic expression showed an association between VitD and Z score, which
may reﬂect a low patient’s compliance.
Conclusions: The results of the study on 21 CF patients show that there is a positive
correlation between BMI and bone disease related to CF. Patients with low BMI had
pathologic values of T score and Z score. The correlation between BMI and bone
disease corroborates the idea that nutritional status is an important prognostic factor.
Our ﬁndings emphasize the role of multiple factors in Cystic Fibrosis phenotype
and the importance (especially for young patients) of achieving and maintaining
a good nutritional status, associated to a good therapeutic compliance, in order to
avoid the negative evolution of pulmonary disease and related bone disorders.
Bibliography: Hecker TM, et al. Drugs 2004, 64: 133–147.
P52 ROLE OF INFECTIOUS PULMONARY COMPLICATIONS IN
LUNG TRANSPLANTATION FOR CYSTIC FIBROSIS: 10 YEARS
FOLLOW-UP
L. Locorriere, C. Scacchi, M. Trancassini, A. Magni, G. Cimino, S. Quattrucci.
Cystic Fibrosis Center, Department of Pediatrics, “Sapienza” University of Rome,
Rome, Italy
Between November 1996 and December 2006, 64 patients (32 M, mean age
25.6±10 years; 32 F mean age 25.1±6.3 years) with end-stage cystic ﬁbrosis
underwent bilateral sequential lung transplantation.
Before transplantation patients’ airways were colonized by Pseudomonas aerugi-
nosa (52 pts), Staphylococcus aureus (7 pts) and Burkholderia cepacia complex (5
pts).
After transplantation patients were observed at 1, 5, 8 and 10 years, examining the
culture of sputum or bronchoalveolar lavage ﬂuid, the serological test for CMV
and the rate of intravenous therapy following bacterial lower airways respiratory
infections.
Of these 64 pts, 34 (54%) are actually alive. 30 pts (46%) died, but only 4 deaths
(1.2%) were caused by infections: 3 pts died in the early post operative period for
sepsis, 1 pt died 14 months after transplantation for P. carinii infection, probably due
to poor compliance to therapy. Opportunistic infections of the lung with P. carinii
occurred in other 2 pts: both responded to treatment.
Early after transplantation the same germs that were present before the transplan-
tation grew again in the culture of sputum or BAL.
The rate of pts colonized by bacteria was 92% at 12 months, stabilized at 100% at 5,
8 and 10 years. The rate of pts with CMV infection was 74% and 28% respectively at
1 and 5 years, zeroing at 8 and 10 years; in our Center CMV infections were treated
in preclinical stage, only 1 pt developed CMV gastric disease, diagnosed by biopsy.
11% of pts had positive sputum or BAL culture for Aspergillus fumigatus during
the ﬁrst year, 7% of pts at 5 years and 22% at 8 years. 2 pts with bronchiolitis
obliterans syndrome had evidence of pulmonary aspergillosis at autopsy and 1 pt
had A. fumigatus infection of the right bronchial anastomosis.
3 pts with B. cepacia colonization who survived the early post operative period did
not have a higher infections rate or a worse outcome than pts not colonized by the
germ.
The rate of intravenous therapy following bacterial respiratory infections was 5%,
20%, 44% respectively at 1, 5, 8 and 10 years after transplantation.
In conclusion, high risk periods for developing infections are the 1st year post
transplantation, when immunosuppressive regimen is intensive, and from 5th year
on, because of the reinduction immunosuppressive therapy after BOS.
In these pts meticulous follow-up, prompt recognition and treatment of pulmonary
infections are essential to prevent poor outcomes.
P53 COLONIC CARCINOMA ON CF PATIENT
M. Collura1, G. Traverso1, F. Ficili1, V. Di Pietrantonio1, T. Pensabene1,
P.E. Marchesa2, F. Pardo1. 1U.O. II Pediatria-Fibrosi Cistica Osp “G. Di Cristina”
ARNAS-Civico Palermo, 2Dipart. Chirurgie ed Oncologia ARNAS – Civico
Palermo, Italy
Case Report: GG, 37-year-old woman, complete form of CF (genotype
F508del/G542X), stable clinical and nutritional trend (BMI 18%, FEV1 42%).
Chronic colonization by Pseudomonas, frequently haemoptysis, subjected to
bronchial ADA for three times. Ursodeoxycolic acid therapy for chronic liver
disease and asymptomatic cholelithiasis.
In July 2006, a sudden abdominal pain appears to the right upper quadrant.
Physical examination shows a treatable abdomen, pain occurs by hard tapping at
the right upper quadrant, moderate hepatomegaly. Plain abdominal X-Ray: normal;
laboratory tests: moderate microcytic hypochromic anemia.
Ultrasound shows a roundish mass in VII-VIII segment of the liver, 6× 5 cm in di-
ameter, dishomogeneous with central liquiﬁed area. The abdominal CT conﬁrms the
presence of roundish formation with diameter 5.6 cm, hypodense in basal condition
with central zone of colliquation (Abscess? New formation of colliquation?).
Due to diagnostic antibody-titer for Enthamoeba Histolytica (1:120) and detection
of trophozoites in the drainage liquid, the patient starts therapy with Metronidazole
and Dehydroemetine.
Abdomen MRI: conﬁrms previous CT report. In January 2007, because of deterio-
ration of general condition, a colonoscopy is carried out that shows a big blackish
vegetating mass; this is easily bleeding with the size about 5 cm, ascribable to the
intestinal location of amoebic formation. Later, an adenocarcinoma was diagnosed
based on histological examination.
In February 2007, the patient undergoes operation of right hepatectomy (resection
of three lesions in IVa, IVb and III segments) and right hemicolectomy. After
operation, pleuric effusion solves after drain. One month later, she starts antiblastic
drug therapy.
At a distance of 8 months the patient is treated by 6 cycles of chemotherapy that
she tolerates well, with a progressive improvement in general condition.
CF is a chronic pathology which causes an increase in risk of developing some
pathologies, such as colon carcinoma with a 6.4 RR.
GI symptoms, particularly if they are persistent or uncountable, have to be always
carefully monitored, with particular attention to increased preponderance of GI
tumours in patients with CF.
Reference(s)
Neglia JP, et al: The risk of cancer in patients with CF. CF and cancer study group. N
Engl J Med. 1995 Feb 23;332(8):494−9.
Misra SP, et al: Ileocecal masses in patients with amebic liver abscess: etiology and
management. Word J Gastroenterol. 2006;12(12):1993−6.
P54 NUTRITIONAL AND RESPIRATORY EFFECTS OF AZITHROMYCIN
LONG-TERM TREATMENT IN CYSTIC FIBROSIS PATIENTS
M.C. Tripodi, G.L. Grzincich, R. Minari, S. Dall’Aglio, G. Pisi. Cystic Fibrosis
Unit, Dep. of Pediatrics, Parma, Italy
In Cystic Fibrosis (CF) patients azithromycin (AZM) in multiple trials has demon-
strated to improve lung function, but there is a large variability in study design,
dosage and outcome measures among these trials. Moreover, long-term studies on
chronic effects of AZM are scanty.
The aim of the study was to evaluate the changes in pulmonary function and
nutritional status in CF patients over 12 months of AZM treatment.
We retrospectively collected the data of 50 patients on daily 250mg AZM contin-
uous therapy; out of these we examined the data of 25 subjects (males 9, mean
age 25.2, range 8−56 years, 50% chronically infected by Pseudomonas aeruginosa)
who concluded a period of 12 months of treatment.
At the baseline and every 3 months we analyzed the changes of BMI, CV, FEV1
and FEF 25−75 by repeated measures analysis of variance. A p value of 0.05 was
considered as signiﬁcant.
Value at month
0
(baseline)
3 6 9 12
BMI 19.8±3 20.2±3.2 20.4±2.8 20.5±3.1 20.4±3.0
CV 79.1±20.2 82.7±19.1 86.6±18.9 85.9±18.2 80.6±19.6
FEV1 61.0±20.7 63.6±17.8 66.3±16.3 66.4±15.6 63.7±21.2
FEF25−75 32.5±22.9 33.9±20.9 34.6±22.3 34.4±19.2 36.4±27.3
The table shows the mean values (+ SD) of BMI, CV, FEV1 and FEF 25−75 at
baseline, 3, 6, 9, 12 months of treatment. The trends are statistically signiﬁcant for
both BMI (p< 0.01) and CV (p< 0.02), but not for FEV1 and FEF25/75.
Our results show that AZM long-term treatment may improve the nutritional status
and respiratory function in CF patients. In addition, the improvement reached after
3 months remains stable throughout the whole year of treatment.
